Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike?

Published:2013-04-24 Issue:2 Volume:30 Page:
ISSN:1357-0560
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Calvani Nicola,Morelli Franco,Chiuri Vincenzo,Gnoni Antonio,Scavelli Claudio,Fedele Palma,Orlando Laura,Maiello Evaristo,Lorusso Vito,Cinieri Saverio

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12032-013-0578-8.pdf

Reference22 articles.

1. Bracarda S, Bellmunt J, Melichar B, Negrier S, Bajetta E, Ravaud A, et al. Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial. BJU Int. 2011;107(2):214–9.

2. Coppin C, Porzsolt F, Autenrieth M, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev. 2004;(3):CD001425. doi: 10.1002/14651858.CD001425.pub2 .

3. Elaidi R-T. What is the best option for second line in long responders to the first-line TKI in metastatic renal cell carcinoma patients: TKI–TKI or TKI-mTORi? 2012; ASCO GU (abstract 375). San Francisco US.

4. Vickers MM, Choueiri TK, Rogers M, Percy A, Finch D, Zama I, et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology. 2010;76(2):430–4.

5. Escudier B, Szczylik C, Porta C, Gore M. Treatment selection in metastatic renal cell carcinoma: expert consensus. Nat Rev Clin Oncol. 2012;9(6):327–37.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current and Emerging Treatments for Metastatic Renal Cell Carcinoma;Current Cancer Drug Targets;2018-05-22

2. Interdisziplinäre Empfehlungen zur Behandlung des metastasierten Nierenzellkarzinoms;Aktuelle Urologie;2017-04-12

3. Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews;Clinical Genitourinary Cancer;2016-04

4. Targeted therapy for renal cell carcinoma: focus on 2nd and 3rd line;Expert Opinion on Pharmacotherapy;2016-01-06

5. Pharmacoeconomic and clinical implications of sequential therapy for metastatic renal cell carcinoma patients in Central and Eastern Europe;Expert Opinion on Pharmacotherapy;2015-11-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3